Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 256   Home Print this page  Email this page Small font size Default font size Increase font size

  Table of Contents    
Year : 2019  |  Volume : 36  |  Issue : 5  |  Page : 373-375  

Drug-resistant tuberculosis: Progress towards shorter and safer regimens

1 Department of Medicine, Kasturba Medical College, Manipal Academy of Higher Education; Manipal McGill Program for Infectious Diseases, Manipal Center for Infectious Diseases,Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, India
2 Manipal McGill Program for Infectious Diseases, Manipal Center for Infectious Diseases, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, Karnataka, India; McGill International Tuberculosis Centre, McGill University, Montreal, Canada

Date of Web Publication23-Aug-2019

Correspondence Address:
Kavitha Saravu
Department of Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Manipal
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/lungindia.lungindia_350_19

Rights and Permissions

How to cite this article:
Saravu K, Pai M. Drug-resistant tuberculosis: Progress towards shorter and safer regimens. Lung India 2019;36:373-5

How to cite this URL:
Saravu K, Pai M. Drug-resistant tuberculosis: Progress towards shorter and safer regimens. Lung India [serial online] 2019 [cited 2021 Apr 12];36:373-5. Available from: https://www.lungindia.com/text.asp?2019/36/5/373/265174

Drug-resistant tuberculosis (DR-TB) continues to be a global health crisis. In 2017, an estimated 558 000 people had rifampicin-resistant TB (RR-TB), and 82% of them had multidrug-resistant TB (MDR-TB); 3.5% of new TB cases and 18% of previously treated cases had MDR/RR-TB. A quarter of the DR-TB cases globally were from India.[1] Only about 25% of these estimated MDR-TB or RR-TB were diagnosed and notified. The remainder were either missing or were on ineffective first-line treatment for the need of drug-susceptibility testing (DST).

To tackle this problem, several countries are scaling up the capacity for universal DST and also introducing newer drugs (e.g. bedaquiline) as well as shorter, individualized regimens, based on DST results.[2]

In a study published in this issue of Lung India, Singh et al. reported on the treatment outcomes of a modified DOTS-plus strategy among 98 consecutive culture-proven adult MDR-TB patients from June 2009 to February 2010 in a single center in North India.[3] Patients were excluded if they had taken second-line drugs for more than 1 month, were pregnant, or had concurrent major medical or psychiatric illness.

The modified DOTS-plus strategy consisted of six drugs (KM, OFX or LFX, ETO, CS, PZA, and EMB) in the intensive phase (IP), followed by four drugs (OFX, ETO, CS, and EMB) in the continuation phase (CP). Treatment included monthly follow-up with clinical, radiological, and bacteriological assessment (sputum smear advised monthly till conversion then quarterly; culture for Mycobacterium tuberculosis at 0, 4, 6, 12, 18, and 24 months). The duration of IP ranged from 6 to 9 months depending on culture results at the 4th month of treatment and CP for a minimum of 18 months. Drugs were provided free of cost, and regular supply of medicines and laboratory supply were ensured by a dedicated team of clinicians, microbiologists, and a laboratory technician. Patient and family members were counseled, and adherence to medication and adverse events (AEs) were monitored.

The MDR-TB cohort had a fairly extensive disease with 95% having bilateral lung involvement. The mean duration of total illness was 4.8 ± 3.6 years, and the duration of anti-TB treatment received by the cohort before referral was 26 ± 12.3 months. The cohort was resistant to a mean of 3.17 ± 1.06 drugs. With the health education, intensive adherence counseling, AE surveillance, and the drug treatment as in the protocol, the sputum smear and culture conversion rates were 75/81 (92.5%) and 71/81 (87.7%), respectively. 81 (82.7%) of patients completed the treatment, with 71 (74.5%) declared successfully cured, 10.2% failed, 7.1% defaulted, and 10.2% expired.

The rate of success in the present study was fairly high, compared to global averages for DR-TB. However, the study excluded 21/132 (15.9%) patients as 8 (6.1%) were exposed to SLDs >1 month and 13 (9.8%) showed non-MDR resistance patterns. This group could have had poor outcomes had they received the standardized regimen. Patients with poor outcomes in the present study were likely to be drug addicts, likely to have >2 previous episodes of TB, and likely to have resistance to both KM and OFX. This highlights the critical need for universal DST, including second-line DST and appropriate treatment based on DST results.

In an individual patient data meta-analysis of 12,030 pulmonary MDR-TB patients, from 25 countries in 50 studies, 7346 (61%) had treatment success, 1017 (8%) had failure or relapse, and 1729 (14%) died.[4] Compared with failure or relapse, treatment success was positively associated with the use of linezolid, levofloxacin, carbapenems, moxifloxacin, bedaquiline, and clofazimine. There was a significant association between reduced mortality and use of linezolid, levofloxacin, moxifloxacin, or bedaquiline. Compared with regimens without any injectable drug, amikacin provided modest benefits, but kanamycin and capreomycin were associated with worse outcomes.

In the present study, AEs were reported in 46 (46.9%) patients; major AEs were reported in 17.4% of patients, with the most common being deafness induced by KM and psychosis by CS. The limitation of the present study is its small sample size and absence of PLHIV among the MDR cohort who are known to have poor outcomes. In addition, this study was performed about a decade ago, and since then, Indian and global guidelines have evolved, and new drugs and regimens have emerged.

In 2010, the Revised National Tuberculosis Control Programme (RNTCP) guidelines for the Programmatic Management of Drug-Resistant Tuberculosis in India were published[5] and updated in 2017.[6] In 2014, the standards for TB care in India were released, comprising 26 standards, with standard 9 specifically addressing the treatment of drug-resistant TB in India.[7]

Based on the WHO recommendations, India adopted in 2017 a shorter MDR-TB regimen lasting 9–12 months for MDR/RR-TB who have not been previously treated for more than 1 month with second-line medicines used in the shorter MDR-TB regimen or in whom resistance to fluoroquinolones and second-line injectable agents has been excluded, which is a standardized regimen, with 4–6 Am-Mfx-Pto (Eto)-Cfz-Z-Hhigh-dose-E/5 Mfx-Cfz-Z-E. India also adopted universal DST for all diagnosed TB patients, when offering an upfront CBNAAT (i.e. Xpert MTB/RIF) to all presumptive TB patients among key populations and incorporated monitoring and management of adverse drug reactions. In March 2017, the RNTCP published a new National Strategic Plan for TB Elimination 2017–2025.[8]

The global guidelines have also advanced in the past few years. In 2019, the WHO published their updated, consolidated guidelines on DR-TB, recommending several major changes.[9] Drugs have been regrouped into three categories and ranked based on the latest evidence about the balance of effectiveness to safety.[4]

Group A are the drugs to be prioritized, namely levofloxacin/moxifloxacin, bedaquiline, and linezolid.[10] Group B are the drugs to be added next, namely clofazimine, cycloserine/terizidone, and Group C which include delamanid are the medicines to be included to complete the regimens and when agents from Groups A and B cannot be used. Drugs no longer recommended are injectables such as kanamycin and capreomycin, given increased risk of toxicity, treatment failure, and relapse associated with their use in longer MDR-TB regimens.

Bedaquiline and delamanid are the newer drugs for the treatment of DR-TB. This year, the US Food and Drug Administration is expected to approve another new drug called Pretomanid.[11] A short course, all-oral treatment of MDR-TB is the major goal today. The Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis 1 study has shown that high-dose moxifloxacin containing short-course regimen was noninferior to a long regimen with respect to the primary efficacy outcome and safety.[12] Other trials are evaluating short-course regimens with bedaquiline against the WHO-recommended regimen.[13] The Nix-TB trial with BPaL regimen (bedaquiline, pretomanid, and linezolid) for XDR-TB has shown very promising results with favorable outcomes in 90% of patients after 6 months of treatment and 6 months of posttreatment follow-up.[11]

The Treatment Shortening of MDR-TB Using Existing and New Drugs Trial is underway to evaluate the effectiveness and safety of a new shorter regimen comprising four oral drugs, including delamanid, linezolid, levofloxacin, and pyrazinamide, for the treatment of fluoroquinolone-sensitive MDR-TB.[14]

The results from these trials provide evidence for adopting a shorter, safer, and more convenient treatment regimen for DR-TB. To support the uptake and scale-up of such shorter regimens, it is paramount that providers and national programs are guided by phenotypic and/or genotypic DST to offer individualized regimens.[2] The scale-up of diagnostics such as CB-NAAT and line probe assays has made DST easier, and technologies such as sequencing are becoming easier and more affordable every passing year. The future of DR-TB treatment heavily relies on our ability to exploit novel DST tools, new drug regimens, and digital adherence support tools. India has a chance to lead from the front in this arena.

   References Top

World Health Organization | Global Tuberculosis Report. World Health Organization; 2018. Available from: http://www.who.int/tb/publications/global_report/en/. [Last accessed on 2019 Jul 22].  Back to cited text no. 1
Kendall EA, Sahu S, Pai M, Fox GJ, Varaine F, Cox H, et al. What will it take to eliminate drug-resistant tuberculosis? Int J Tuberc Lung Dis 2019;23:535-46.  Back to cited text no. 2
Singh A, Prasad R, Kushwaha RA, Srivastava R, Giridhar BH, Balasubramanian V, et al. Treatment outcome of multidrugresistant tuberculosis with modified DOTSplus strategy: A 2 years' experience. Lung India 2019;36: [In this issue].  Back to cited text no. 3
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: An individual patient data meta-analysis. Lancet 2018;392:821-34.  Back to cited text no. 4
Available from: http://planningcommission.nic.in/reports/genrep/health/RNTCP_2011.pdf. [Last accessed on 2019 Jul 23].  Back to cited text no. 5
Guideline for PMDT in India 2017 : Central TB Division. Available from: https://tbcindia.gov.in/index1.php?lang=1&level=2&sublinkid=4780 &lid=3306. [Last accessed on 2019 Jul 22].  Back to cited text no. 6
Purty AJ. Standards for TB Care in India (STCI), World Health Organization (India), Central TB Division, Ministry of health and Family Welfare, Government India; 2014.  Back to cited text no. 7
National Strategic Plan 2017-2025 for TB Elimination in India : Central TB Division. Available from: https://tbcindia.gov.in/index1.php?lang=1&level=1&sublinkid=4768&lid=3266. [Last accessed on 2019 Jul 22].  Back to cited text no. 8
World Health Organization | WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Available from: https://www.who.int/tb/publications/2019/consolidated-guidelines-drug-resistant-TB-treatment/en/. [Last accessed on 2019 Jul 25].  Back to cited text no. 9
World Health Organization | Rapid Communication: Key Changes to Treatment of Multidrug – And Rifampicin-Resistant Tuberculosis (MDR/RR-TB). World Health Organization. Available from: http://www.who.int/tb/publications/2018/rapid_communications_MDR/en/. [Last accessed on 2019 Jul 22].  Back to cited text no. 10
FDA Advisory Committee Votes Favorably on the Question of the Effectiveness and Safety of Pretomanid in Combination with Bedaquiline and Linezolid for Treatment of Highly Drug-Resistant Forms of Tuberculosis | TB Alliance. Available from: https://www.tballiance.org/news/fda-advisory-committee-votes-favorably -question-effectiveness-and-safety-pretomanid-combination. [Last accessed on 2019 Jul 25].  Back to cited text no. 11
Nunn AJ, Phillips PP, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. Atrial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med 2019;380:1201-13.  Back to cited text no. 12
Moodley R, Godec TR; STREAM Trial Team. Short-course treatment for multidrug-resistant tuberculosis: The STREAM trials. Eur Respir Rev 2016;25:29-35.  Back to cited text no. 13
Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, et al. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment shortening of MDR-TB using existing and new drugs, MDR-END): Study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials 2019;20:57.  Back to cited text no. 14


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded540    
    Comments [Add]    

Recommend this journal